Patients Experienced Pseudoprogression to Anti-PD1/PD-L1 Inhibitor Have Better Response Than Those Without in Lung Cancer

被引：0
|
作者：
Zhao, W. [1 ,2 ]
Zhou, F. [1 ,2 ]
Li, W. [2 ,3 ]
Qian, D. [1 ,2 ]
Zhang, J. [1 ,2 ]
Wu, F. [1 ,2 ]
Zhou, C. [1 ,2 ]
机构：
[1] Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Tongji Univ, Thorac Canc Inst, Sch Med, Shanghai, Peoples R China
[3] Shanghai Pulm Hosp, Dept Radiol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Pseudoprogression; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P01.10
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [21] Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
    Gianoncelli, Letizia
    Spitaleri, Gianluca
    Passaro, Antonio
    Radice, Davide
    Fumagalli, Caterina
    Del Signore, Ester
    Stati, Valeria
    Catania, Chiara Matilde
    Guerini-Rocco, Elena
    Barberis, Massimo
    De Marinis, Filippo
    ANTICANCER RESEARCH, 2020, 40 (01) : 427 - 433
  • [22] Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
    Banna, Giuseppe Luigi
    Cantale, Ornella
    Bersanelli, Melissa
    Del Re, Marzia
    Friedlaender, Alex
    Cortellini, Alessio
    Addeo, Alfredo
    ONCOLOGY REVIEWS, 2020, 14 (02) : 135 - 143
  • [23] Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
    Wang, Luyao
    Ma, Qingxia
    Yao, Ruixue
    Liu, Jia
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 79
  • [24] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer Patients
    Maniaci, Joseph
    Mills, Anne
    Dillon, Patrick
    Gaughan, Elizabeth
    Jenkins, Taylor
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 160 - 161
  • [25] Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer
    Shukuya, Takehito
    Carbone, David P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : 976 - 988
  • [26] MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Breast Cancer Patients
    Maniaci, Joseph
    Mills, Anne
    Dillon, Patrick
    Gaughan, Elizabeth
    Jenkins, Taylor
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 160 - 161
  • [27] Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study
    Yang, Jin
    Zeng, Ran
    Zhou, Jianping
    Luo, Lifeng
    Lyu, Mengchen
    Liu, Fang
    Sun, Xianwen
    Zhou, Ling
    Wang, Xiaofei
    Bao, Zhiyao
    Chen, Wei
    Dumoulin, Daphne W.
    Gao, Beili
    Xiang, Yi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (06) : 1038 - +
  • [28] Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment
    Cheng, Jiaxing
    2020 INTERNATIONAL CONFERENCE ON ENERGY, ENVIRONMENT AND BIOENGINEERING (ICEEB 2020), 2020, 185
  • [29] Systemic analysis of innate responses to anti-PD1/PD-L1 treatment in a melanoma model
    Gassen, Rodrigo
    Welm, Alana
    Bonorino, Cristina
    CANCER RESEARCH, 2018, 78 (13)
  • [30] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
12345